SE1146865T3 - - Google Patents
Info
- Publication number
- SE1146865T3 SE1146865T3 SE99902781T SE99902781T SE1146865T3 SE 1146865 T3 SE1146865 T3 SE 1146865T3 SE 99902781 T SE99902781 T SE 99902781T SE 99902781 T SE99902781 T SE 99902781T SE 1146865 T3 SE1146865 T3 SE 1146865T3
- Authority
- SE
- Sweden
- Prior art keywords
- sotalol
- antiarrhythmic
- laevo
- dextro
- ratio
- Prior art date
Links
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical class CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 abstract 4
- 229960002370 sotalol Drugs 0.000 abstract 4
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 3
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 2
- 206010047302 ventricular tachycardia Diseases 0.000 abstract 2
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 abstract 1
- 241000700198 Cavia Species 0.000 abstract 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 abstract 1
- 244000166550 Strophanthus gratus Species 0.000 abstract 1
- 239000002876 beta blocker Substances 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 abstract 1
- 229960003343 ouabain Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN89KO1999 IN188162B (en]) | 1999-02-05 | 1999-02-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE1146865T3 true SE1146865T3 (en]) | 2003-09-02 |
| SE1146865T5 SE1146865T5 (en]) | 2003-11-18 |
Family
ID=38668683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE99902781T SE1146865T5 (en]) | 1999-02-05 | 1999-02-22 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6281246B2 (en]) |
| EP (1) | EP1146865B9 (en]) |
| JP (1) | JP2002536324A (en]) |
| CN (1) | CN1149987C (en]) |
| AT (1) | ATE241349T1 (en]) |
| AU (1) | AU761521C (en]) |
| BR (1) | BR9915951A (en]) |
| CA (1) | CA2348882C (en]) |
| CZ (1) | CZ20011807A3 (en]) |
| DE (1) | DE69908421T2 (en]) |
| DK (1) | DK1146865T3 (en]) |
| ES (1) | ES2195538T3 (en]) |
| HK (1) | HK1041206B (en]) |
| HU (1) | HU224033B1 (en]) |
| IN (1) | IN188162B (en]) |
| PL (1) | PL351143A1 (en]) |
| PT (1) | PT1146865E (en]) |
| RU (1) | RU2213560C2 (en]) |
| SE (1) | SE1146865T5 (en]) |
| WO (1) | WO2000045807A1 (en]) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060105044A1 (en) | 2004-05-20 | 2006-05-18 | Singh Bramah N | Sustained release formulations of sotalol |
| PT2024329E (pt) * | 2006-05-18 | 2013-11-04 | Dompe Spa | (2r)-2-[(4-sulfonil)aminofenil]propanamidas e composições farmacêuticas que as contenham |
| CN102329254B (zh) * | 2010-07-12 | 2014-02-05 | 上海奥博生物医药技术有限公司 | 一种制备n-[4-[1-羟基-2-[(1-甲基乙基)胺基]乙基]甲磺酰胺盐酸盐的方法 |
| BE1021320B1 (fr) * | 2014-08-27 | 2015-10-29 | Hyloris Pharmaceuticals SA | Composition pharmaceutique prete a l'emploi |
| BE1021328B1 (fr) * | 2014-08-27 | 2015-10-30 | Hyloris Pharmaceuticals SA | Composition pharmaceutique prete a l'emploi |
| FR3050297A1 (fr) * | 2016-04-13 | 2017-10-20 | Assist Publique - Hopitaux De Paris | Methode de determination de la susceptibilite d'induction d'une torsade de pointes |
| CN109419779B (zh) * | 2017-09-04 | 2021-05-25 | 鲁南制药集团股份有限公司 | 一种盐酸索他洛尔制剂 |
| CN109419780B (zh) * | 2017-09-04 | 2021-05-11 | 张家港市中医医院 | 一种盐酸索他洛尔片剂及其制备方法 |
| CN108785268B (zh) * | 2018-01-17 | 2021-05-28 | 威海华新药业集团有限公司 | 一种盐酸索他洛尔制剂及其制备方法 |
| US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089526A (en) * | 1983-05-23 | 1992-02-18 | Bristol-Myers Company | Antiarrhythmic class III process |
| JPH01165569A (ja) * | 1987-12-22 | 1989-06-29 | Mitsui Toatsu Chem Inc | 光学活性なソタロールの製造方法 |
| IES61567B2 (en) * | 1994-02-17 | 1994-11-16 | Russinsky Ltd | Pharmaceutical products |
-
1999
- 1999-02-05 IN IN89KO1999 patent/IN188162B/en unknown
- 1999-02-22 DE DE69908421T patent/DE69908421T2/de not_active Expired - Fee Related
- 1999-02-22 AU AU22960/99A patent/AU761521C/en not_active Ceased
- 1999-02-22 CZ CZ20011807A patent/CZ20011807A3/cs unknown
- 1999-02-22 CA CA002348882A patent/CA2348882C/en not_active Expired - Fee Related
- 1999-02-22 HU HU0104175A patent/HU224033B1/hu active IP Right Grant
- 1999-02-22 WO PCT/IB1999/000322 patent/WO2000045807A1/en active IP Right Grant
- 1999-02-22 EP EP99902781A patent/EP1146865B9/en not_active Expired - Lifetime
- 1999-02-22 PT PT99902781T patent/PT1146865E/pt unknown
- 1999-02-22 SE SE99902781T patent/SE1146865T5/xx unknown
- 1999-02-22 DK DK99902781T patent/DK1146865T3/da active
- 1999-02-22 PL PL99351143A patent/PL351143A1/xx not_active IP Right Cessation
- 1999-02-22 RU RU2001111808/14A patent/RU2213560C2/ru not_active IP Right Cessation
- 1999-02-22 CN CNB998136395A patent/CN1149987C/zh not_active Expired - Fee Related
- 1999-02-22 ES ES99902781T patent/ES2195538T3/es not_active Expired - Lifetime
- 1999-02-22 HK HK02102291.0A patent/HK1041206B/en not_active IP Right Cessation
- 1999-02-22 BR BR9915951-1A patent/BR9915951A/pt not_active IP Right Cessation
- 1999-02-22 AT AT99902781T patent/ATE241349T1/de not_active IP Right Cessation
- 1999-02-22 JP JP2000596927A patent/JP2002536324A/ja active Pending
-
2000
- 2000-12-19 US US09/739,276 patent/US6281246B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU761521C (en) | 2004-01-22 |
| CA2348882C (en) | 2004-07-13 |
| DE69908421T2 (de) | 2004-03-18 |
| HUP0104175A2 (hu) | 2002-04-29 |
| EP1146865A1 (en) | 2001-10-24 |
| PT1146865E (pt) | 2003-08-29 |
| JP2002536324A (ja) | 2002-10-29 |
| HUP0104175A3 (en) | 2002-12-28 |
| IN188162B (en]) | 2002-08-31 |
| BR9915951A (pt) | 2001-08-21 |
| US20010004643A1 (en) | 2001-06-21 |
| CA2348882A1 (en) | 2000-08-10 |
| DE69908421D1 (de) | 2003-07-03 |
| HK1041206B (en) | 2003-10-31 |
| CN1328453A (zh) | 2001-12-26 |
| PL351143A1 (en) | 2003-03-24 |
| HK1041206A1 (en) | 2002-07-05 |
| AU761521B2 (en) | 2003-06-05 |
| WO2000045807A1 (en) | 2000-08-10 |
| EP1146865B1 (en) | 2003-05-28 |
| DK1146865T3 (da) | 2003-09-22 |
| ES2195538T3 (es) | 2003-12-01 |
| HU224033B1 (hu) | 2005-05-30 |
| US6281246B2 (en) | 2001-08-28 |
| RU2213560C2 (ru) | 2003-10-10 |
| CN1149987C (zh) | 2004-05-19 |
| CZ20011807A3 (cs) | 2001-08-15 |
| ATE241349T1 (de) | 2003-06-15 |
| AU2296099A (en) | 2000-08-25 |
| EP1146865B9 (en) | 2004-03-17 |
| SE1146865T5 (en]) | 2003-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE1146865T3 (en]) | ||
| Corne et al. | A possible correlation between drug-induced hallucinations in man and a behavioural response in mice | |
| Zemlan et al. | Activation of lordotic responding in female rats by suppression of serotonergic activity | |
| ES8505519A1 (es) | Un procedimiento para la preparacion de 14-fluoromorfinanos utiles como analgesicos, narcoticos y-o agentes anorexicos. | |
| IL142921A0 (en) | USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS | |
| ES2164040T1 (es) | Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos. | |
| IL143901A0 (en) | Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia | |
| AU5090796A (en) | Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence | |
| BRPI0314308B8 (pt) | antagonistas de opióide, seus usos, e composição farmacêutica | |
| PL357944A1 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
| CO5271710A1 (es) | Combinanciones de un inhibidor de cinasa de tirosina receptora con un compuesto organico capaz de enlazarse con glicorpoteina acido-a | |
| BR0115847A (pt) | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos | |
| CA2408417A1 (en) | Local anesthetic methods and kits | |
| AU2003301020A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| RU99107280A (ru) | Фармацевтический препарат для лечения гипертрофии простаты и рака простаты и способ лечения | |
| Leal et al. | Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors | |
| MXPA03007885A (es) | Norbuprenorfina n-but-3-enilo y metodos de uso. | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| HUT74948A (en) | Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema | |
| NO20020731D0 (no) | Kosttilskudd for å forbedre den muskul¶re energimetabolismen som innbefatter en alkanoylkarnitin og ribose | |
| Kimoto et al. | Effects of [1-desamino-8-D-arginine] vasopressin and papaverine on rabbit renal pelvis | |
| BR0008057A (pt) | Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada | |
| Taber et al. | Antagonism of the analgesic effect of opioid and non-opioid agents by p-chlorophenylalanine (PCPA) | |
| MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
| Wahlström et al. | Metabolic interaction between morphine and naloxone in human liver. A common pathway of glucuronidation? |